Clinical Trials
The Department of Psychiatry & Behavioral Sciences invites research subjects to participate in studies aimed at improving the diagnosis and treatment of schizophrenia, psychosis (e.g., hearing voices, paranoia), bipolar disorder, depression, and anxiety.
Our clinical trial team consists of skilled psychiatrists and research coordinators who will carefully monitor subjects during their participation. Browse the active studies below or call our Clinical Research Program office at 312-503-7071.
Feinberg Clinical Trials
Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.
| Trials |
|---|
Northwestern University The Department of Psychiatry and Behavioral Sciences, Clinical Research Program (NU CRP) Recruitment PipelineThe recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’… The recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’s disease, Tourette’s Syndrome, etc. NU CRP conducts basic, translational and clinical research. Personal Health Information (PHI) will not be collected. All information collected in this recruitmentregistry is based on the patient self-report. You will be contacted to answer additional questions by someone in the study staff and to determine your eligibility for the current studies. Copy Study URL to Clipboard Copy |
The IMPACT TD study – a Tardive Dyskinesia Observational StudyThis study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a … This study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life. Eligibility Criteria Patients diagnosed with Tardive dyskinesia, above 18 years of age Location(s)
IRB number STU00219451 Keywords Tardive dyskinesia Copy Study URL to Clipboard Copy |
The OARS-7 Study for Major Depressive DisorderThe purpose of the J&J OARS-7 Study is to evaluate a medication to treat depression (MDD) and depression with insomnia (MDDIS). This study is for intended for people diagnosed with depression who have only experienced a partial response to their current antidepressant treatment; in other words, they … The purpose of the J&J OARS-7 Study is to evaluate a medication to treat depression (MDD) and depression with insomnia (MDDIS). This study is for intended for people diagnosed with depression who have only experienced a partial response to their current antidepressant treatment; in other words, they are still currently experiencing symptoms of depression. The main goal of this study is to learn how safe the study drug is and how well the study drug works when taken with the antidepressants you are currently taking for depression. What will I do if I participate? There are two parts of this study. In part 1, participants will take part in 8 study visits in-person at Northwestern Hospital where they will be given either study drug or a placebo. After part one, participants may be offered the option to continue into part 2, which is an open-label phase (everyone receives study drug). Visits will include clinical assessments and questionnaires regarding mental health symptoms. Eligibility Criteria Eligibility Criteria
Location(s)
IRB number STU00223008 Copy Study URL to Clipboard Copy |
An Open-Label Study of Xanomeline/Trospium Chloride for SchizophreniaThe purpose of this study is to evaluate a recently FDA-approved medication to treat schizophrenia. This study is for intended for people diagnosed with schizophrenia who are not able to tolerate or are not happy with their current antipsychotic treatment; in other words, they are still currently experiencing symptoms, … The purpose of this study is to evaluate a recently FDA-approved medication to treat schizophrenia. This study is for intended for people diagnosed with schizophrenia who are not able to tolerate or are not happy with their current antipsychotic treatment; in other words, they are still currently experiencing symptoms, experiencing side effects, or are not responding to their medication. There is no placebo in this study, so everyone will get treated with the study medication xanomeline/trospium chloride. What will I do if I participate? Participants will take part in 13 study visits in-person at Northwestern Hospital. Visits 1 and 2 are to evaluate potential participants' eligibility to take part in the study. Visits 3-12 are also in-person and take place over 6 months and will involve receiving the study medication. The last visit is a brief follow-up visit. Copy Study URL to Clipboard Copy |